Lyell Immunopharma Inc. (LYEL)
0.61
0.04 (6.18%)
At close: Jan 15, 2025, 2:45 PM
Ratios (Annual)
Discover comprehensive ratio statement breakdowns that reveal insights into revenue, expenses, and beyond.
| Year | FY23 | FY22 | FY21 | FY20 | FY19 |
| PE Ratio | -2.08 | -180.35 | -6.58 | -20.98 | -34.35 |
| PS Ratio | 3.75K | 10.12 | 176.41 | 536.97 | 6.34K |
| PB Ratio | 0.74 | 1.03 | 2.02 | 5.80 | 10.21 |
| P/FCF Ratio | -2.93 | -4.42 | -9.8 | -19.61 | 177.78 |
| P/OCF Ratio | -2.97 | -5.06 | -14.88 | -25.89 | 105.51 |
| OCF/S Ratio | -1.26K | -2 | -11.85 | -20.74 | 60.08 |
| Debt / Equity Ratio | 0.10 | 0.08 | 0.07 | 0.08 | 0.07 |
| Quick Ratio | 16.07 | 17.59 | 13.40 | 12.53 | 19.97 |
| Current Ratio | 16.07 | 17.59 | 13.40 | 12.53 | 19.97 |
| Asset Turnover | 0.00 | 0.09 | 0.01 | 0.01 | 0.00 |
| Interest Coverage | n/a | n/a | n/a | n/a | n/a |
| Return on Equity (ROE) | -0.36 | -0.01 | -0.31 | -0.28 | -0.3 |
| Return on Assets (ROA) | -0.31 | -0.01 | -0.25 | -0.22 | -0.22 |
| Return on Capital (ROIC) | -0.35 | -0.2 | -0.2 | -0.25 | -0.19 |
| Dividend Yield | n/a | n/a | n/a | n/a | n/a |
| Payout Ratio | n/a | n/a | n/a | n/a | n/a |
| Gross Profit Margin | 100.00% | 80.55% | -36.48% | 3.62% | 100.00% |
| Net Profit Margin | -180.49K% | -5.61% | -2.68K% | -2.56K% | -18.46K% |
| Pretax Profit Margin | -180.49K% | -216.24% | -2.35K% | -2.64K% | -19.69K% |
| Operating Profit Margin | -190.01K% | -216.24% | -2.02K% | -2.73K% | -15.54K% |
| FCF Margin | -127.98K% | -228.89% | -1.80K% | -2.74K% | 3.57K% |
| EBITDA Margin | -174.43K% | -196.79% | -1.88K% | -2.68K% | -15.35K% |